Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Jimmy Carter Credits Merck's Keytruda For Cancer-Free Success

This article was originally published in Scrip

Executive Summary

While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register